Novartis Aktie
WKN: 907122 / ISIN: US66987V1098
|
08.07.2025 07:14:46
|
Press Release: Novartis receives approval for -2-
References
1. Eight African countries participated in Swissmedic's Marketing
Authorization for Global Health Products (MAGHP) procedure
https://www.swissmedic.ch/swissmedic/en/home/about-us/development-cooperation/marketing-authorisation-for-global-health-products.html
for Coartem Baby -- Burkina Faso, Cote d'Ivoire, Kenya, Malawi,
Mozambique, Nigeria, Tanzania and Uganda -- and are expected to approve
the medicine following approval by Swissmedic. These eight countries
account for 47% of estimated cases in 2023, according to the WHO's Global
Health Observatory
https://www.who.int/data/gho/data/indicators/indicator-details/GHO/estimated-number-of-malaria-deaths
2. WHO. Malaria vaccines (RTS,S and R21)
https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccine#::text=Malaria%20vaccines%20should%20be%20provided%20to%20children%20in%20a%20schedule,
age%20based%20on%20operational%20considerations.
3. Reddy, Valentina et al. Global estimates of the number of pregnancies at
risk of malaria from 2007 to 2020: a demographic study. The Lancet Global
Health, Volume 11, Issue 1, e40 - e47
4. Ceesay SJ et al. Malaria Prevalence among Young Infants in Different
Transmission Settings, Africa. Emerg Infect Dis. 2015 Jul;21(7):1114-21.
doi: 10.3201/eid2107.142036. PMID: 26079062; PMCID: PMC4480393.
5. D'Alessandro U, et al. Malaria in infants aged less than six months - is
it an area of unmet medical need? Malar J. 2012 Dec 2;11:400. doi:
10.1186/1475-2875-11-400. PMID: 23198986; PMCID: PMC3529680.
6. Dobbs, et al. Plasmodium malaria and antimalarial antibodies in the first
year of life. Parasitology. 2016;143(2):129-138.
doi:10.1017/S0031182015001626
7. WHO. Malaria. https://www.who.int/news-room/fact-sheets/detail/malaria
# # #
Novartis Media Relations
E-mail: media.relations@novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
(END) Dow Jones Newswires
July 08, 2025 01:15 ET (05:15 GMT)
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novartis AG
|
12:26 |
Angespannte Stimmung in Zürich: SLI mittags schwächer (finanzen.at) | |
|
12:26 |
Verluste in Zürich: SMI mittags schwächer (finanzen.at) | |
|
09:28 |
Aufschläge in Zürich: SMI liegt zum Start im Plus (finanzen.at) | |
|
09:28 |
Gewinne in Zürich: SLI beginnt Montagshandel mit Gewinnen (finanzen.at) | |
|
30.04.26 |
Pluszeichen in Zürich: SLI steigt schlussendlich (finanzen.at) | |
|
30.04.26 |
Aufschläge in Zürich: SMI liegt letztendlich im Plus (finanzen.at) | |
|
30.04.26 |
SMI aktuell: SMI legt am Donnerstagnachmittag zu (finanzen.at) | |
|
30.04.26 |
Starker Wochentag in Zürich: SLI mit Kursplus (finanzen.at) |
Analysen zu Novartis AG
| 29.04.26 | Novartis Neutral | UBS AG | |
| 29.04.26 | Novartis Buy | Deutsche Bank AG | |
| 29.04.26 | Novartis Sell | Goldman Sachs Group Inc. | |
| 29.04.26 | Novartis Equal Weight | Barclays Capital | |
| 28.04.26 | Novartis Halten | DZ BANK |
Aktien in diesem Artikel
| Novartis AG (Spons. ADRS) | 124,00 | -1,59% |
|
| Novartis AG | 124,48 | -1,24% |
|